Addition of Atezolizumab to mFOLFOX6 Ups DFS in Stage III dMMR Colon Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Amazon Big Spring Sale - Up to 40% off

Medically reviewed by Carmen Pope, BPharm. Last updated on April 3, 2026.

via HealthDay

FRIDAY, April 3, 2026 -- For patients with stage III mismatch repair-deficient (dMMR) colon cancer, the addition of the anti-programmed death ligand 1 agent atezolizumab to a modified regimen of fluorouracil, oxaliplatin, and leucovorin (mFOLFOX6) is associated with significantly improved disease-free survival, according to a study published in the March 26 issue of the New England Journal of Medicine.

Frank A. Sinicrope, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues randomly assigned patients with resected stage III dMMR tumors to receive either adjuvant atezolizumab plus mFOLFOX6 for six months, with atezolizumab continued as monotherapy for six months, or mFOLFOX6 alone for six months (355 and 357 patients, respectively).

The researchers found that the three-year disease-free survival was 86.3 and 76.2 percent in the atezolizumab-mFOLFOX6 and the mFOLFOX6-alone groups, respectively, at a median follow-up of 40.9 months (hazard ratio for disease recurrence or death, 0.50). Adverse events of grade 3 or 4 occurred in 84.1 and 71.9 percent of patients who received atezolizumab plus mFOLFOX6 or mFOLFOX6 alone, respectively.

"Our findings highlight why every patient diagnosed with colon cancer should have MMR testing," Sinicrope said in a statement. "This testing helps identify Lynch syndrome and also shows whether a patient may benefit from immunotherapy."

Several authors disclosed ties to biopharmaceutical companies, including Genentech, a member of the Roche group, which partially funded the study.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-04 01:41

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords